Privia Health Group, Inc. (NASDAQ:PRVA) Shares Acquired by Caitong International Asset Management Co. Ltd

Caitong International Asset Management Co. Ltd raised its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 2,115.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,323 shares of the company’s stock after acquiring an additional 3,173 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in Privia Health Group were worth $75,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of PRVA. Van Berkom & Associates Inc. acquired a new stake in Privia Health Group during the 1st quarter valued at approximately $45,207,000. Nuveen LLC acquired a new stake in Privia Health Group during the 1st quarter valued at approximately $26,899,000. Durable Capital Partners LP lifted its stake in Privia Health Group by 3.4% during the 4th quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company’s stock valued at $224,587,000 after acquiring an additional 378,255 shares during the period. Royce & Associates LP acquired a new stake in Privia Health Group during the 1st quarter valued at approximately $6,818,000. Finally, BlackBarn Capital Partners LP lifted its stake in Privia Health Group by 65.8% during the 4th quarter. BlackBarn Capital Partners LP now owns 663,397 shares of the company’s stock valued at $12,969,000 after acquiring an additional 263,397 shares during the period. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on PRVA. Barclays lifted their price objective on shares of Privia Health Group from $23.00 to $24.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 27th. Piper Sandler decreased their target price on shares of Privia Health Group from $36.00 to $35.00 and set an “overweight” rating for the company in a research note on Monday, August 11th. JPMorgan Chase & Co. boosted their target price on shares of Privia Health Group from $29.00 to $32.00 and gave the company an “overweight” rating in a research note on Wednesday, May 28th. JMP Securities reiterated a “market outperform” rating and issued a $29.00 target price on shares of Privia Health Group in a research note on Monday, April 28th. Finally, Evercore ISI decreased their target price on shares of Privia Health Group from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Privia Health Group has a consensus rating of “Buy” and an average price target of $28.00.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA opened at $21.27 on Friday. The firm has a market cap of $2.61 billion, a PE ratio of 193.38, a PEG ratio of 2.59 and a beta of 0.80. The firm has a fifty day moving average of $21.09 and a 200 day moving average of $22.75. Privia Health Group, Inc. has a one year low of $16.47 and a one year high of $26.09.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.03). The company had revenue of $521.15 million during the quarter, compared to analysts’ expectations of $466.97 million. Privia Health Group had a return on equity of 2.13% and a net margin of 0.78%. Privia Health Group’s revenue was up 23.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.19 EPS. On average, equities analysts predict that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.